Xarelto治疗静脉血栓疗效怎么样？

Rivaroxaban (Xarelto) is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban (Xarelto) does not inhibit thrombin (activated factor II) and has not been shown to have an effect on platelets. Rivaroxaban (Xarelto) is a highly selective, oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: by inhibiting factor Xa, it can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis. Rivaroxaban (Xarelto) does not inhibit thrombin (activated factor II) and has not been shown to have an effect on platelets. A dose-dependent inhibitory effect of rivaroxaban (Xarelto) on factor Xa activity has been observed in humans. Clinical studies have shown that rivaroxaban (Xarelto) can effectively prevent deep vein thrombosis after peri-hip fracture surgery. It has good safety and is worthy of clinical promotion.

Recently, a study published in the Journal of Thrombosis showed that monotherapy with the new oral anticoagulant rivaroxaban (Xarelto) can effectively treat deep vein thrombosis and pulmonary embolism and prevent their subsequent recurrence in Chinese patients. The study randomly assigned Chinese patients to two groups: oral rivaroxaban (Xarelto, Xarelto) (15 mg twice daily for 3 weeks, followed by 20 mg once daily) or standard therapy (injectable enoxaparin bridged with a dose-adjusted vitamin K antagonist) for 3, 6, or 12 months. The results showed that the two groups were equally effective in treating acute symptomatic deep vein thrombosis and/or symptomatic pulmonary embolism, and the rivaroxaban (Xarelto) group had a lower rate of major bleeding. In addition, the study also found that rivaroxaban (Xarelto, Xarelto) has similar efficacy in high-risk groups, such as elderly or frail patients, patients with kidney damage, cancer patients, and patients with larger clots in the body. In addition, rivaroxaban (Xarelto) was well tolerated by Chinese patients and did not require routine coagulation monitoring, dose adjustments, or dietary restrictions.